Last $0.22 USD
Change Today 0.00 / 0.00%
Volume 11.0K
ILIU On Other Exchanges
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

interleukin genetics inc (ILIU) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/1/13 - $0.46
52 Week Low
07/21/14 - $0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

interleukin genetics inc (ILIU) Related Businessweek News

No Related Businessweek News Found

interleukin genetics inc (ILIU) Details

Interleukin Genetics, Inc. engages in development and commercialization of personalized health products that help individuals to improve and maintain their health through preventive measures primarily in the United States. It provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand; and PST test to analyze genetic variations associated with inflammation and identify individuals with risk for periodontal disease. The company markets its Inherent Health brand of genetic tests through its e-commerce Website and under contract with Amway and various regional weight management focused organizations; and PST tests directly to dentists and periodontists. It is also involved in the development of osteoarthritis genetic tests that analyze adult joint diseases. The company has research collaborations with various universities and clinics for the research and development of genetic tests. Interleukin Genetics, Inc. was founded in 1986 and is based in Waltham, Massachusetts.

interleukin genetics inc (ILIU) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $360.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $252.5K
Chief Marketing Officer
Total Annual Compensation: $257.9K
Compensation as of Fiscal Year 2013.

interleukin genetics inc (ILIU) Key Developments

Interleukin Genetics, Inc., Annual General Meeting, Jul 23, 2014

Interleukin Genetics, Inc., Annual General Meeting, Jul 23, 2014., at 10:00 US Eastern Standard Time. Location: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.. Agenda: To elect Kenneth S. Kornman and Dayton Misfeldt as Class II directors for a three-year term expiring at its 2017 annual meeting; to ratify the appointment of Grant Thornton LLP as its independent public accounting firm for the fiscal year ending December 31, 2014; to consider an advisory vote on compensation of its named executive officers, as disclosed in this proxy statement; and to consider any other business that is properly presented at the meeting.

Interleukin Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

Interleukin Genetics, Inc. reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenue of $487,566 against $487,393 a year ago. Loss from operations was $1,666,512 against 1,087,593 a year ago. Loss from operations before income taxes was $1,664,519 against 1,201,580 a year ago. Net loss was $1,664,519 or $0.01 basic and diluted net loss per common share against $1,201,580 or $0.03 basic and diluted net loss per common share a year ago. The change in total revenue is primarily attributable to decreased genetic testing revenue quarter to quarter, offset in part by breakage revenue recognized from deferred revenue recorded in the first quarter of 2014 and increased royalty revenue.

Interleukin Genetics, Inc., Q1 2014 Earnings Call, May 14, 2014

Interleukin Genetics, Inc., Q1 2014 Earnings Call, May 14, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.22 USD 0.00

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies

Industry Analysis


Industry Average

Valuation ILIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.1x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at